Corticosteroid treatment for problematic infantile hemangioma: Evidence does not support an increased risk for cerebral palsy

Pediatrics

Volumn 121, Issue 6, 2008, Pages 1251-1252

  Greene, Arin K ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE; GLUCOCORTICOID;

ABDOMINAL PAIN; BODY HEIGHT; BODY WEIGHT; CEREBRAL PALSY; COGNITIVE DEFECT; CORTICOSTEROID THERAPY; DERMATOMYCOSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; ENCEPHALOMALACIA; HEAD CIRCUMFERENCE; HEMANGIOMA; HIRSUTISM; HUMAN; INFANT; INJECTION SITE REACTION; LUNG DYSPLASIA; MOON FACE; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NOTE; PERSONALITY DISORDER; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PREMATURITY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SPASTIC DIPLEGIA; SPASTICITY; STOMACH IRRITATION; SYSTEMIC THERAPY; TENDON REFLEX; TREATMENT DURATION; VERY LOW BIRTH WEIGHT; ARTICLE; CHEMICALLY INDUCED DISORDER; NEWBORN; PRESCHOOL CHILD; RISK FACTOR;

CEREBRAL PALSY; CHILD, PRESCHOOL; GLUCOCORTICOIDS; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; RISK FACTORS;

EID: 48949105372     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2418     Document Type: Note

References (28)

1. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350(13):1304-1312
2. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146
3. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007; 119(4):716-721
4. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-1623
5. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6). Available at: www.pediatrics.org/cgi/ content/full/119/6/e1239
6. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
7. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
8. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease.
9. Pediatrics. 2005;115(3):681-687
10. André P, Thebaud B, Odievre MH, et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med. 2000;26(10): 1496-1500
11. Rademaker KJ, Uiterwaal C, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr. 2007; 150(4):351-357
12. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopment outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007;120(1):40-48
13. Bennett ML, Fleischer AB, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas. Arch Dermatol. 2001;137(9):1208 -1213
14. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg. 2004;113(1): 53-60
15. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-969
16. Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: experience and guidelines for monitoring. Int Pediatr. 1999;14(3):146-153
17. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticoste- roid therapy for airway hemangiomas. Mayo Clin Proc. 2004; 79(2):243-245
18. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol. 1997;14(3):173-179
19. Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional cortico- steroid therapy for infantile hemangiomas. Plast Reconstr Surg.
20. 1989;83(3):459 -467
21. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 pt 1):527-530
22. Dubois J, Hershow L, Carmont L, et al. Toxicity profile of interferon alfa-2B in children: a prospective evaluation. J Pe-
23. diatr. 1999;135(6):782-785
24. Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004;114(7):
25. 1231-1236
26. Haisley-Royster Camille, Enjolras O, Frieden IJ, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002;24(6): 459-462
27. Scarcella JV, Dykes ER, Anderson R. Hemangiomas of the parotid gland. Plast Reconstr Surg. 1965;36:38 -47
28. Williams HB. Hemagniomas of the parotid gland in children. Plast Reconstr Surg. 1975;56(1):29 -34